Shares of Arrowhead Pharmaceuticals ARWR were flat in after-market trading after the company reported Q3 results.
Quarterly Results
Earnings per share were down 123.08% year over year to ($0.29), which missed the estimate of ($0.20).
Revenue of $45,891,000 rose by 67.63% from the same period last year, which beat the estimate of $37,520,000.
Looking Ahead
Earnings guidance hasn't been issued by the company for now.
Arrowhead Pharmaceuticals hasn't issued any revenue guidance for the time being.
Conference Call Details
Date: Aug 05, 2021
Time: 04:30 PM
ET Webcast URL: https://edge.media-server.com/mmc/p/uikmqr9b
Recent Stock Performance
52-week high: $93.66
52-week low: $32.86
Price action over last quarter: Up 2.38%
Company Profile
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
